Stay updated on SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial page.

Latest updates to the SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check19 days agoChange DetectedThe page’s footer/version label has been updated from “Revision: v3.5.2” to “Revision: v3.5.3,” reflecting a backend or display version change rather than a change to the clinical study details.SummaryDifference0.0%

- Check26 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check47 days agoChange DetectedAdded the MeSH term 'Cutaneous neuroendocrine carcinoma' and updated the page revision from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check69 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.0%

- Check90 days agoChange DetectedGastric cancer was added to the list of conditions for the study, broadening the potential population the page pertains to. A new Genetic and Rare Diseases Information Center resource was added under Resources, and the site revision banner updated from v3.4.1 to v3.4.2.SummaryDifference0.2%

- Check97 days agoChange DetectedRevision: v3.4.1 was added and v3.4.0 removed, indicating a version update that does not change study details or how the page is used.SummaryDifference0.0%

Stay in the know with updates to SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial page.